LAWRENCEVILLE, N.J.,
May 9, 2016 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) announced today that the
Company will host a conference call to discuss financial results
for the quarter ended March 31, 2016
and provide an update on its development programs for ThermoDox®,
its proprietary heat-activated liposomal encapsulation of
doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into
a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday,
May 16, 2016. To participate in the call, interested parties
may dial 1-888-359-3624 (Toll-Free/North
America) or 1-719-457-2085 (International/Toll) and ask for
the Celsion Corporation 1st Quarter 2016 Earnings Call
(Conference Code: 7064110) to register ten minutes before the call
is scheduled to begin. The call will also be broadcast live over
the internet at www.celsion.com.
The call will be archived for replay on Monday, May 16, 2016 and will remain available
until Monday, May 30, 2016. The
replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820
(International/Toll) using Conference Code: 7064110. An audio
replay of the call will also be available on the Company's website,
www.celsion.com, for 30 days after 2:00 p.m.
EDT on Monday, May 16,
2016.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our website:
www.celsion.com (CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-corporation-to-hold-first-quarter-2016-financial-results-conference-call-on-monday-may-16-2016-300264389.html
SOURCE Celsion Corporation